Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2023 Filed Apr 7, 2023 15:38 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 27,720 | $367.77 | $10,194,473.52 |
DisclosureSEC source: 0001209191-23-023712 · doc4.xml · nonDerivative · entry 4 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,181,628 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.275 to $368.27, inclusive. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 15:38 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 16,321 | $366.80 | $5,986,510.16 |
DisclosureSEC source: 0001209191-23-023712 · doc4.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,209,348 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.27 to $367.265, inclusive. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 15:38 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 22,196 | $365.70 | $8,117,143.79 |
DisclosureSEC source: 0001209191-23-023712 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,225,669 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.265 to $366.23, inclusive. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 15:38 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 16,242 | $364.98 | $5,927,956.43 |
DisclosureSEC source: 0001209191-23-023712 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,247,865 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $364.265 to $365.26, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| April 05, 2023 Filed Apr 6, 2023 17:21 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 9,444 | $364.21 | $3,439,618.13 |
DisclosureSEC source: 0001209191-23-023555 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,264,107 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $364.00 to $364.385, inclusive. Read SEC document |
| April 05, 2023 Filed Apr 6, 2023 17:21 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 60,259 | $363.24 | $21,888,298.38 |
DisclosureSEC source: 0001209191-23-023555 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,273,551 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.00 to $363.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 15:53 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 100 | $351.50 | $35,150.00 |
DisclosureSEC source: 0001209191-23-022522 · doc4.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,333,810 Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 15:53 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 116,614 | $350.88 | $40,917,870.16 |
DisclosureSEC source: 0001209191-23-022522 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,333,910 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.50 to $351.47, inclusive. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 15:53 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 93,286 | $350.01 | $32,650,566.43 |
DisclosureSEC source: 0001209191-23-022522 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,450,524 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.50 to $350.4975, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 14:25 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 260 | $343.54 | $89,320.40 |
DisclosureSEC source: 0001209191-23-021975 · doc4.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,543,810 Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 14:25 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 45,143 | $342.83 | $15,476,284.40 |
DisclosureSEC source: 0001209191-23-021975 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,544,070 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.50 to $343.39, inclusive. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 14:25 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 159,597 | $341.78 | $54,546,264.68 |
DisclosureSEC source: 0001209191-23-021975 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,589,213 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.50 to $342.49, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 14:31 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 18,024 | $336.61 | $6,067,022.59 |
DisclosureSEC source: 0001209191-23-021155 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,748,810 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.50 to $336.79, inclusive. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 14:31 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 181,976 | $335.75 | $61,097,532.12 |
DisclosureSEC source: 0001209191-23-021155 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,766,834 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.50 to $336.495, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:04 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 34 | $333.60 | $11,342.40 |
DisclosureSEC source: 0000059478-23-000125 · wf-form4_167951545125988.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,995 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:08 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 30 | $333.60 | $10,008.00 |
DisclosureSEC source: 0000059478-23-000127 · wf-form4_167951570693841.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,922 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:10 UTC |
Hedley Mary LynneDirector
|
GrantCommon Stock | 30 | $333.60 | $10,008.00 |
DisclosureSEC source: 0000059478-23-000129 · wf-form4_167951581609755.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:13 UTC |
JOHNSON KIMBERLY HDirector
|
GrantCommon Stock | 29 | $333.60 | $9,674.40 |
DisclosureSEC source: 0000059478-23-000131 · wf-form4_167951598095181.xml · nonDerivative · entry 1 JOHNSON KIMBERLY H · CIK 0001658089 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,046 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:14 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 43 | $333.60 | $14,344.80 |
DisclosureSEC source: 0000059478-23-000133 · wf-form4_167951608764026.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,879 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:16 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 15 | $333.60 | $5,004.00 |
DisclosureSEC source: 0000059478-23-000135 · wf-form4_167951619779073.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,635 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:18 UTC |
TAI JACKSON PDirector
|
GrantCommon Stock | 6 | $333.60 | $2,001.60 |
DisclosureSEC source: 0000059478-23-000137 · wf-form4_167951630549329.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,519 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 20:31 UTC |
Weems AlonzoEVP, ERM & CECO
|
SaleCommon Stock | 1,000 | $318.85 | $318,850.00 |
DisclosureSEC source: 0000059478-23-000113 · wf-form4_167873947197922.xml · nonDerivative · entry 1 Weems Alonzo · CIK 0001869672 · EVP, ERM & CECO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,908 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 5, 2022. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:31 UTC |
Dozier EricEVP, HR & Diversity
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000105 · wf-form4_167779268700027.xml · derivative · entry 4 Dozier Eric · CIK 0001955972 · EVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,602 shares Expires 2023-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:31 UTC |
Dozier EricEVP, HR & Diversity
|
Tax withholdingCommon Stock | 714 | $311.22 | $222,211.08 |
DisclosureSEC source: 0000059478-23-000105 · wf-form4_167779268700027.xml · nonDerivative · entry 2 Dozier Eric · CIK 0001955972 · EVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,808 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:31 UTC |
Dozier EricEVP, HR & Diversity
|
Exercise / conversionCommon Stock | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000105 · wf-form4_167779268700027.xml · nonDerivative · entry 1 Dozier Eric · CIK 0001955972 · EVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:34 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,890 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000107 · wf-form4_167779282954589.xml · derivative · entry 4 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,890 shares Expires 2023-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:34 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
Tax withholdingCommon Stock | 843 | $311.22 | $262,358.46 |
DisclosureSEC source: 0000059478-23-000107 · wf-form4_167779282954589.xml · nonDerivative · entry 2 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,861 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:34 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
Exercise / conversionCommon Stock | 1,890 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000107 · wf-form4_167779282954589.xml · nonDerivative · entry 1 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:36 UTC |
Weems AlonzoEVP, ERM & CECO
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,779 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000109 · wf-form4_167779298259738.xml · derivative · entry 3 Weems Alonzo · CIK 0001869672 · EVP, ERM & CECO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,779 shares Expires 2023-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:36 UTC |
Weems AlonzoEVP, ERM & CECO
|
Tax withholdingCommon Stock | 793 | $311.22 | $246,797.46 |
DisclosureSEC source: 0000059478-23-000109 · wf-form4_167779298259738.xml · nonDerivative · entry 2 Weems Alonzo · CIK 0001869672 · EVP, ERM & CECO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,908 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:36 UTC |
Weems AlonzoEVP, ERM & CECO
|
Exercise / conversionCommon Stock | 1,779 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000109 · wf-form4_167779298259738.xml · nonDerivative · entry 1 Weems Alonzo · CIK 0001869672 · EVP, ERM & CECO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:39 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
GrantRestricted Stock Unit · Derivative | 1,274 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000111 · wf-form4_167779311613673.xml · derivative · entry 3 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,274 Underlying: Common Stock · 1,274 shares Expires 2027-03-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:31 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
SaleCommon Stock | 600 | $322.47 | $193,482.00 |
DisclosureSEC source: 0000059478-23-000103 · wf-form4_167770626037162.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,578 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16,2022. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:47 UTC |
TAI JACKSON PDirector
|
GrantCommon Stock | 6 | $327.51 | $1,965.06 |
DisclosureSEC source: 0000059478-23-000084 · wf-form4_167710238309810.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,456 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:49 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 35 | $327.51 | $11,462.85 |
DisclosureSEC source: 0000059478-23-000086 · wf-form4_167710254348899.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,772 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:51 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 30 | $327.51 | $9,825.30 |
DisclosureSEC source: 0000059478-23-000088 · wf-form4_167710265738457.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,639 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:53 UTC |
Hedley Mary LynneDirector
|
GrantCommon Stock | 30 | $327.51 | $9,825.30 |
DisclosureSEC source: 0000059478-23-000090 · wf-form4_167710278960618.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:55 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 44 | $327.51 | $14,410.44 |
DisclosureSEC source: 0000059478-23-000092 · wf-form4_167710292072728.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,783 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:57 UTC |
JOHNSON KIMBERLY HDirector
|
GrantCommon Stock | 30 | $327.51 | $9,825.30 |
DisclosureSEC source: 0000059478-23-000094 · wf-form4_167710301616620.xml · nonDerivative · entry 1 JOHNSON KIMBERLY H · CIK 0001658089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,010 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:59 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 15 | $327.51 | $4,912.65 |
DisclosureSEC source: 0000059478-23-000096 · wf-form4_167710312267960.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:32 UTC |
Norton JohnaEVP, Global Quality
|
GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000077 · wf-form4_167701512962950.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,408 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:35 UTC |
Van Naarden JacobEVP and CEO Loxo@Lilly
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000079 · wf-form4_167701530938901.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · EVP and CEO Loxo@Lilly 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,785 shares Expires 2023-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:35 UTC |
Van Naarden JacobEVP and CEO Loxo@Lilly
|
Tax withholdingCommon Stock | 1,314 | $335.01 | $440,203.14 |
DisclosureSEC source: 0000059478-23-000079 · wf-form4_167701530938901.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · EVP and CEO Loxo@Lilly 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,845 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:35 UTC |
Van Naarden JacobEVP and CEO Loxo@Lilly
|
Exercise / conversionCommon Stock | 2,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000079 · wf-form4_167701530938901.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP and CEO Loxo@Lilly 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
SaleCommon Stock | 2,500 | $346.47 | $866,175.00 |
DisclosureSEC source: 0000059478-23-000069 · wf-form4_167641273108663.xml · nonDerivative · entry 3 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,926 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 2, 2022. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:34 UTC |
Ashkenazi AnatEVP & CFO
|
GrantCommon Stock | 6,693 | $345.12 | $2,309,888.16 |
DisclosureSEC source: 0000059478-23-000045 · wf-form4_167641043020681.xml · nonDerivative · entry 1 Ashkenazi Anat · CIK 0001761679 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,120 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:37 UTC |
Dozier EricEVP, HR & Diversity
|
GrantCommon Stock | 1,820 | $345.12 | $628,118.40 |
DisclosureSEC source: 0000059478-23-000047 · wf-form4_167641058187302.xml · nonDerivative · entry 1 Dozier Eric · CIK 0001955972 · EVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,920 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:40 UTC |
Hakim AnatEVP, GC & Secretary
|
GrantRestricted Stock Unit · Derivative | 4,442 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000049 · wf-form4_167641078384260.xml · derivative · entry 2 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,442 Underlying: Common Stock · 4,442 shares Expires 2024-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:40 UTC |
Hakim AnatEVP, GC & Secretary
|
GrantCommon Stock | 9,072 | $345.12 | $3,130,928.64 |
DisclosureSEC source: 0000059478-23-000049 · wf-form4_167641078384260.xml · nonDerivative · entry 1 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,189 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:43 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
GrantCommon Stock | 5,204 | $345.12 | $1,796,004.48 |
DisclosureSEC source: 0000059478-23-000051 · wf-form4_167641096188829.xml · nonDerivative · entry 1 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,814 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.